Triglycerides, long chain; triglycerides, medium chain
Brand: CarbZero®; Betaquik®
PBAC's latest decision on Triglycerides, long chain; triglycerides, medium chain: Recommended (2017). Considered for Ketogenic diet for intractable seizures, glucose transport protein defect, or pyruvate dehydrogenase deficiency (long chain); dietary management of conditions requiring medium chain triglycerides including chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, and fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders (medium chain).
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Patients with intractable seizures requiring ketogenic diet; glucose transport protein defect; pyruvate dehydrogenase deficiency (long chain); chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, or fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders (medium chain).
Therapy area
Metabolic
Line of therapy
Not applicable
Evidence base
Other
Economic model
BIA only
ICER note
not-modelled — minor submission for formulation/product-form change with no economic evaluation